Enveric Biosciences (ENVB) Income from Continuing Operations (2010 - 2026)
Enveric Biosciences (ENVB) posted Income from Continuing Operations of 1633473.0 for Q1 2026, down 84.34% sequentially from 886115.0 in Q4 2025, and up 25.24% YoY from 1304270.58 in Q1 2025.
Enveric Biosciences (ENVB) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Enveric Biosciences has reported Income from Continuing Operations for 17 years, with the latest figure at 1633473.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 25.24% year-over-year to 1633473.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6912438.0 (up 25.7% YoY) and the FY2025 annual result came in at 5621814.0, up 41.29% from the prior year.
- Income from Continuing Operations retreated to 1633473.0 in Q1 2026 per ENVB's latest filing, from 886115.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 3621767.0 in Q4 2023 and troughed at 6356053.0 in Q2 2023.
- A 5-year average of 2576792.71 and a median of 2478912.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations soared 224.34% in 2023, then plunged 187.1% in 2024.
- Over 5 years, Income from Continuing Operations stood at 2912734.0 in 2022, then jumped by 224.34% to 3621767.0 in 2023, then slumped by 187.1% to 3154646.0 in 2024, then surged by 71.91% to 886115.0 in 2025, then slumped by 84.34% to 1633473.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 1633473.0, 886115.0, and 1873669.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 81.49 Mn |
| 10 | Enveric Biosciences | 5.58 Mn | -2.71 Mn | - | -3.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.63 Mn |
| Dec 31, 2025 | -886,115.00 |
| Sep 30, 2025 | -1.87 Mn |
| Jun 30, 2025 | -2.52 Mn |
| Mar 31, 2025 | -2.18 Mn |
| Dec 31, 2024 | -3.15 Mn |
| Sep 30, 2024 | -2.08 Mn |
| Jun 30, 2024 | -1.88 Mn |
| Mar 31, 2024 | -2.46 Mn |
| Dec 31, 2023 | 3.62 Mn |
| Sep 30, 2023 | -2.82 Mn |
| Jun 30, 2023 | -6.36 Mn |
| Mar 31, 2023 | -4.68 Mn |
| Dec 31, 2022 | -2.91 Mn |
| Sep 30, 2022 | -2.48 Mn |
| Jun 30, 2022 | -4.71 Mn |
| Mar 31, 2022 | -4.80 Mn |
| Dec 31, 2021 | -50.98 Mn |
| Sep 30, 2021 | -4.25 Mn |
| Jun 30, 2021 | -3.45 Mn |